What Did This CEO Just Do with Personal Shares of Karyopharm Therapeutics (NASDAQ: KPTI)?

By Carrie Williams

Yesterday, the CEO of Karyopharm Therapeutics (KPTIResearch Report), Michael Kauffman, sold shares of KPTI for $290.6K.

In addition to Michael Kauffman, 4 other KPTI executives reported Sell trades in the last month. This is Kauffman’s first transaction since reporting a Buy transaction on VSTM back in October 2018

See today’s analyst top recommended stocks >>

Based on Karyopharm Therapeutics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $18.1 million and GAAP net loss of $48.65 million. In comparison, last year the company earned revenue of $206K and had a GAAP net loss of $58.21 million. The company has a one-year high of $20.09 and a one-year low of $3.92. The Company has a Price to Book ratio of 16.8520.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.